Get the Stockscreener App
1.26
3.08%
-0.04
After Hours:
1.23
-0.03
-2.38%
Bone Biologics Corp stock is traded at $1.26, with a volume of 50,194.
It is down -3.08% in the last 24 hours and down -27.17% over the past month.
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
See More
Previous Close:
$1.30
Open:
$1.28
24h Volume:
50,194
Relative Volume:
0.02
Market Cap:
$3.04M
Revenue:
-
Net Income/Loss:
$-8.95M
P/E Ratio:
-0.1371
EPS:
-9.19
Net Cash Flow:
$-9.56M
1W Performance:
+0.00%
1M Performance:
-27.17%
6M Performance:
-16.00%
1Y Performance:
+167.46%
1-Day Range:
$1.224
$1.29
1-Week Range:
$1.14
$1.68
52-Week Range:
$0.3701
$10.56
Bone Biologics Corp Stock (BBLG) Company Profile
Name
Bone Biologics Corp
Sector
Industry
Phone
(781) 552-4452
Address
2 BURLINGTON WOODS DRIVE,, BURLINGTON
Compare BBLG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBLG
Bone Biologics Corp
|
1.26 | 3.04M | 0 | -8.95M | -9.56M | -9.19 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Bone Biologics Corp Stock (BBLG) Latest News
Bone Biologics Corp (BBLGW) Quarterly 10-Q Report - Quartzy
Orthobiologics Market Is Expected To Reach a Revenue Of USD 11.7 Bn By 2033, at 5.7% CAGR: Dimension Market Research - OrthoSpineNews
Orthobiologics Market Is Expected To Reach a Revenue Of USD - GlobeNewswire
Learn to Evaluate (BBLGW) using the Charts - Stock Traders Daily
OFIX INVESTORS: OrthoFix Medical Inc. Stockholders Should Contact Robbins LLP About Joining the Pending OFIX Class Action - The Malaysian Reserve
Theradaptive Announces Peer-Reviewed Publication in Spine of Preclinical Spinal Fusion Study of OsteoAdapt™ SP - OrthoSpineNews
Bone Growth Products Market Insights Report, 2024-2029: - GlobeNewswire
Long Term Trading Analysis for (BBLGW) - Stock Traders Daily
Orthobiologics Global Market Analysis, Trends, Growth, Research And Forecast 2033 - openPR
Spine Biologics Market Report 2024Spine Biologics Market Trends And Share - openPR
BBLGBone Biologics Corp Latest Stock News & Market Updates - StockTitan
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors - StockTitan
Therealreal Inc (REAL) Recovers 161.90% From Low: Sitting In The Catbird Seat? - Stocks Register
BBLG’s 2023 Market Dance: Down -67.26% – Time to Invest? - The InvestChronicle
Stock Market Recap: Bone Biologics Corp (BBLG) Concludes at 1.48, a -6.92 Surge/Decline - The Dwinnex
Tetrous®Inc. Announces Issue of an Additional U.S. Patent Related to EnFix® Demineralized Bone Fiber Implants for Sports Medicine Surgical Procedures - OrthoSpineNews
TETROUS®, INC. ANNOUNCES ISSUE OF AN ADDITIONAL U.S. PATENT RELATED TO ENFIX® DEMINERALIZED BONE FIBER IMPLANTS FOR SPORTS MEDICINE SURGICAL PROCEDURES - PR Newswire
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.55% - MSN
Ortho Biological Products Market Giants Spending Is Going to Boom - Bacterial Vaccines Market with ...
Bone Biologics announces director resignation - Investing.com India
Bone Biologics announces director resignation By Investing.com - Investing.com South Africa
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.55% - MSN
Bone Void Fillers Market 2024By Industry Outlook, Future Trends, Growth Analysis And Forecast To 2033 - openPR
Was there any good news for Bone Biologics Corp (BBLG) stock in the last session? - US Post News
Bone Biologics Corp (BBLG) Stock: Navigating a Year of Volatility - The InvestChronicle
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients - Benzinga
In the Green: Bone Biologics Corp (BBLG) Closes at 1.52, Up/Down -26.92 from Previous Day - The Dwinnex
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.55% - MSN
Cutera (CUTR) Stock Drops 5.14% Amid Financial Challenges - GuruFocus.com
Bone Biologics (NASDAQ:BBLG) Stock Quotes, Forecast and News Summary - Benzinga
Orthobiologics Market Industry Analysis 2024 Future Scope, - openPR
A closer look at BBLG’s price-to-free cash flow ratio - US Post News
Bone Biologics Corp (BBLG) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Wall Street today: US stocks surge stops as investors pause after big US Fed rate cut, Nike gains 6.59% | Stock Market News - Mint
Wall Street today: US stocks surge stops as investors pause after big US Fed rate cut, Nike gains 6.59% - Mint
Bone Biologics Corp [BBLG] Is Currently 20.23 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
Orthobiologics Market See Incredible Growth 2024-2031 | Zimmer - openPR
SLNO Skyrockets 800%, BWAY Blasts Past 400%Were You On Board? - RTTNews
Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors - CNBC
BioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Update - MarketBeat
Bausch Reportedly Eyes A Sale; Could J&J Or AbbVie Buy It? - Investor's Business Daily
Nothing is Better Than Bone Biologics Corp (BBLG) stock at the moment - SETE News
Orthobiologics Market 2024 SWOT Analysis, Key Business Strategies by Leading Industry Players and Forecast 2033 - Cauverynews
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Reviewing BioLargo (NASDAQ:BLGO) and Loop Industries (NASDAQ:LOOP) - Defense World
Why Bausch + Lomb Rallied Today - The Motley Fool
Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues - AOL
Bausch + Lomb Stock Jumps Amid Reports Of A Sale - Investopedia
BBLG’s price-to-free cash flow ratio: What it means for investors - US Post News
Bone Biologics Corp’s Banking’s 100-Day Moving Average at 1.5338: Will the Stock Break Through? - The InvestChronicle
Bone Biologics rises 5% on $2M equity offering - MSN
Bone Biologics Corp Stock (BBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):